Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Ketamine for Alcoholics Backed in New Licensing Deal: The Dose (Correct)

Aug. 15, 2022, 8:09 PM

Welcome to my latest weekly newsletter about the cannabis and psychedelics industries. It’s hard to cover all the fascinating research in psychedelics, but addiction treatment is a recurrent theme. This week I look at the prospects for treating one of the most widely used and abused drugs: alcohol.

A biotech takes aim at addiction

A new licensing deal for ketamine in the US shows the growing ambitions of the psychedelics industry to treat addiction.

Awakn Life Sciences Corp., a London-based biotech company, is licensing its ketamine protocol to treat alcohol abuse to Revitalist Lifestyle and Wellness Ltd. Awakn Chief Executive Officer Anthony ...